Session 6: Late-breaking abstracts

In a new session, participants heard two late-breaking abstracts highlighting high-impact research.

Sustained and clinically meaningful improvements in quality of life during treatment with navenibart: Interim results for the ALPHA-SOLAR trial

Dr Raffi Tachdijian from the University of California-Los Angeles, United States, presented data on the impact of a potential new HAE treatment, navenibart, on patient quality of life. He suggested that navenibart was well tolerated, and led to an average 90% reduction in HAE attack rates compared to baseline. Patients treated with the medicine reported improved quality of life across all areas studied.

On-demand oral sebetralstat for hereditary angioedema attacks in children aged 2-11: Interim analysis of KONFIDENT-KID

Dr Emel Aygören-Pürsün from Goethe University in Germany was asked to present findings from a trial of sebetralstat in children aged 2-11. She suggested the ongoing study was designed to investigate the safety and efficacy of sebetralstat orally disintegrating tablets in children with HAE due to C1 inhibitor deficiency. She concluded that children with HAE and their caregivers experience significant burden from HAE attacks and the currently available injectable on-demand treatments. In this study, attacks occurred in all locations, including in the larynx, but the mean number of attacks per month was 0.7, and that 88.9% of attacks were mild to moderate at the time of treatment. The medicine was considered generally safe and well-tolerated, and it demonstrated rapid symptom relief and complete attack resolution.